$CNS Pharmaceuticals (CNSP.US)$
This is all in the SEC filings, peeps. Have a look! Know what you are invested in. $CNSP is your ticket to retirement and what people call “ FUCK YOU MONEY” 💰🔥🚀💵

$SOBR Safe (SOBR.US)$
@Rivera
This one is heating up. See my post below for details.

$CNS Pharmaceuticals (CNSP.US)$
$CNSP While big pharma giants like Merck, Bristol-Myers Squibb, Roche, Eli Lilly, Sanofi, AbbVie, Novocure, Tocagen, Merck KGaA, and Orbus Therapeutics who are placed in the key players category for GBM treatment, continue to struggle in the GBM space, CNSP’s Berubicin is way ahead of the game—currently in a pivotal, Phase 3-like trial and has become become the first anthracycline to cross the blood-brain barrier and directly target GBM.

Despite years of researc...

$CNS Pharmaceuticals (CNSP.US)$
$CNSP Do you know why FDA fast tracked and gave OD designation?

Did some extensive research last night.

Over the past decade, Lomustine has been evaluated in several clinical trials for the treatment of recurrent glioblastoma (GBM).

Below is a tabulated summary of six notable studies:

While Lomustine has been a standard treatment option for recurrent GBM, Berubicin's early clinical data suggest potential advantages in efficacy. The current trial aims to...

$CNS Pharmaceuticals (CNSP.US)$
This long weekend was planned ….Prepping for breakout move to $0.30 Next, $0.50-$1.00 Will be quick. Good luck to all !!!

$CNS Pharmaceuticals (CNSP.US)$
a post on X

$CNS Pharmaceuticals (CNSP.US)$
$CNSP Spend some time and read this from Jan 2025 to know what is coming...

https://www.sec.gov/Archives/edgar/data/1729427/000168316825000077/cns_ex9901.htm

$CNS Pharmaceuticals (CNSP.US)$
$CNSP When CNSP received the FDA Orphan Drug approval , CEO of Stocktwits was all over this 😉
https://www.prnewswire.com/news-releases/cns-announces-the-fda-has-granted-orphan-drug-designation-for-brain-cancer-drug-berubicin-301074249.html

$CNS Pharmaceuticals (CNSP.US)$
$CNSP CNSP’s latest 10Q filing reveals a massive hidden value that investors should not overlook! With milestone payments valuing shares at $36.48–$48.64, this sets a baseline valuation far above the current market price. The Glioblastoma (GBM) market is $10.3B, and with only 75M O/S, a fair market cap projection could push CNSP to $165/share if Berubicin captures significant market share.

$RETA who is CNSP's collaborator and partner in Berucibin was acquired by...